Titlebook: Ovarian Cancer Biomarkers; Mapping to Improve O Khalid El Bairi Book 2021 The Editor(s) (if applicable) and The Author(s), under exclusive

Pessimistic

書目名稱Ovarian Cancer Biomarkers影響因子(影響力)




書目名稱Ovarian Cancer Biomarkers影響因子(影響力)學(xué)科排名




書目名稱Ovarian Cancer Biomarkers網(wǎng)絡(luò)公開度




書目名稱Ovarian Cancer Biomarkers網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Ovarian Cancer Biomarkers被引頻次




書目名稱Ovarian Cancer Biomarkers被引頻次學(xué)科排名




書目名稱Ovarian Cancer Biomarkers年度引用




書目名稱Ovarian Cancer Biomarkers年度引用學(xué)科排名




書目名稱Ovarian Cancer Biomarkers讀者反饋




書目名稱Ovarian Cancer Biomarkers讀者反饋學(xué)科排名

eulogize

Devastate

Communicate

頭盔

Book 2021ling in the advancement of precision medicine. The initial chapter discusses our current understanding of the origin, development, progression and tumorigenesis of ovarian cancer. In turn, the book highlights the development of resistance, disease occurrence, and poor prognosis that are the hallmark

Bph773

Mutter

Genetic Alterations in Ovarian Cancer as Prognostic and Predictive Biomarkers of Therapy Response a of the solid cancers that have benefited from genetic biomarkers for the implementation of targeted agents such as PARP inhibitors in clinical practice. This progress is discussed in this chapter based on recent studies and clinical trials.

Obstruction

Cutting-Edge Technologies for Ovarian Cancer: An Overview of the Impact of Genetic Testing, Next-Gepact on patients’ outcomes according to the latest research findings. We finally depict the potential of single-cell sequencing in understanding OC heterogeneity based on recent proof-of-concept studies.

侵略者

ASTER

The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkerinatorial approaches. In this chapter, the clinical impact of genetics, biomarkers, and therapy in OC is reviewed based on the hallmarks of cancer. We particularly present a special emphasis on druggable targets investigated in phase II/III clinical trials for OC.